Weill Cornell
New York, NY
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
DREAMM12
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Accepting patients
IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Learn more- Natural Killer Cells (Allogeneic)
- Phase 1/2
Accepting patients
APG-2575
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Learn more- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
D-ClaPd
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Learn more- Monoclonal Antibody
- CD38
- Phase 2
Accepting patients
ISB 1442
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- CD38
- CD47
- Phase 1/2
- Has results
Accepting patients
EZM0414
A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Learn more- SET2D Inhibitor
- Phase 1
1 hidden based on your filters. Show All